New Horizons – Rare GIST Sub-Types
Rare GIST Sub-Types presented by Dr. Jason Sicklick of Moores UCSD Cancer Center at New Horizons 2019 in Wayne, NJ.
New Horizons – Understanding the Promises and Limitations of Real World Evidence
Video titled Understanding the Promises and Limitations of Real World Evidence presented by Lucinda S. Orsini of ISPOR at New Horizons 2019.
New Horizons – The Role of ctDNA in GIST
Dr. Ciara Kelly of Memorial Sloan Kettering Cancer Center at presented The Role of ctDNA in GIST at New Horizons 2019 in Wayne, NJ.
New Horizons – Interventional Radiology Approaches to Treat Recurrent GIST
The presentation "Interventional Radiology Approaches to Treat Recurrent GIST" was given at New Horizons 2019 in Wayne, NJ by Dr. Joseph Erinjeri of Memorial Sloan Kettering Cancer Center.
New Horizons – Real World Evidence in Action – Part 2
This video is of Rodrigo Salas of Fundación GIST México presenting Real World Evidence at New Horizons 2019 in Wayne, NJ.
New Horizons – Understanding the Concept of “Precision Oncology”
Understanding the Concept of "Precision Oncology" in patient-friendly language presented by Dr. Jason Sicklick of Moores Cancer Center UCSD at New Horizons 2019.
LRG Assisted in CAP Guidelines Modifications with a Diagnostic Algorithm
The LRG, in collaboration with the Pediatric & SDH-Deficient GIST Consortium and key opinion leaders among the GIST pathology community (with Dr. Brian Rubin taking the lead), played a significant role in changing CAP Guidelines. CAP Guidelines are protocols for pathologists to instruct them on the process of diagnosing a disease based on tumor tissue samples.
LRG Webcast: Optimizing GIST Treatment – Hebrew Subtitles
This webcast was originally recorded May 21, 2019. Follow this link for webcast with Hebrew Subtitles. Listen to the webcast - Hebrew subtitles Are you interested in optimizing your treatment? In [...]
Rozlytrek™ (entrectinib) by Approved by FDA
The FDA granted the approval of Rozlytrek™ (entrectinib) for the treatment of adults with ROS1-positive, metastatic non-small cell lung cancer (NSCLC), The FDA has also granted accelerated approval to Rozlytrek for the treatment of [...]
LRG Webcast Series: When to Consider Surgery
Most GIST patients will see a surgeon at some point during their treatment. This webcast will address the issues surrounding the decision to have an operation and considers that surgical options depend on a number of factors such as tumor location, tumor size, tumor number, response to drug therapy, and risk of recurrence.